The future of COVID-19 management: A spotlight on respirology
10 Jan 2024;
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Indications/Uses : Treatment of infections due to susceptible organisms including UTI, skin & resp tract infections eg, severe nosocomial pneumonia infections caused by multi-resistant microorganisms.
Indications/Uses : Treatment of conditions for which corticosteroid therapy is indicated except adrenocortical-deficiency states, for which hydrocortisone w/ supplementary fludrocortisone is preferred.
Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg
Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.
Indications/Uses : Treatment of essential HTN. Replacement therapy in patients receiving telmisartan & amlodipine besilate. Add on therapy in patients whose BP is not adequately controlled on telmisartan or amlodipine monotherapy. Initial therapy in patients who are likely to need multiple drugs to achieve BP goals.
Indications/Uses : Gastric
ulcer. Improvement
of gastric mucosa lesion (erosion, flare & edema) of the following diseases: Acute
gastritis, acute aggravated period of chronic gastritis.
Sign Out
